The 483

Tag

Pfizer

14 stories

FDA

FDA Cleared Lilly Foundayo in $9.3B Obesity Race

FDA Cleared Lilly Foundayo in $9.3B Obesity Race
FDA

Celcuity Beats Piqray in Phase 3, Shares Jump 15%

Celcuity Beats Piqray in Phase 3, Shares Jump 15%
FDA

FDA Cleared Regeneron's Otarmeni; Last Big Pharma Signs MFN Deal

FDA Cleared Regeneron's Otarmeni; Last Big Pharma Signs MFN Deal
FDA

Novo Targets FDA Filing for Etavopivat After 27% VOC Reduction

Novo Targets FDA Filing for Etavopivat After 27% VOC Reduction
FDA

Merck Hits 55% NSCLC ORR With MK-2010, Won't Commit to Phase 3

Merck Hits 55% NSCLC ORR With MK-2010, Won't Commit to Phase 3
Deals

Raised $625M at $16 a Share, Kailera Tops Moderna's 2018 IPO Record

Raised $625M at $16 a Share, Kailera Tops Moderna's 2018 IPO Record
Deals

Priced at $16, Kailera Raises $625M in Largest Biotech IPO Since 2018

Priced at $16, Kailera Raises $625M in Largest Biotech IPO Since 2018
Deals

Cleared $22B: Q1 2026 Obesity Deals Top 2025's Full-Year Total

Cleared $22B: Q1 2026 Obesity Deals Top 2025's Full-Year Total
FDA

Darovasertib Hits 6.9-Month PFS Goal, Ideaya Plans H2 FDA Filing

Darovasertib Hits 6.9-Month PFS Goal, Ideaya Plans H2 FDA Filing
FDA

TrumpRx Lists AbbVie's Humira at $950/Month Next to Cheaper Biosimilars

TrumpRx Lists AbbVie's Humira at $950/Month Next to Cheaper Biosimilars
FDA

Lunsekimig Fails Eczema Phase 2, Leaving Dupixent Without a Successor

Lunsekimig Fails Eczema Phase 2, Leaving Dupixent Without a Successor
FDA

Lipocine's PPD Drug Fails Phase 3, Stock Craters 77%

Lipocine's PPD Drug Fails Phase 3, Stock Craters 77%
FDA

Pfizer Scraps COVID Vaccine Trial; 80% of Recruits Failed Screening

Pfizer Scraps COVID Vaccine Trial; 80% of Recruits Failed Screening
FDA

Trump's 100% Pharma Tariff: Who Pays, Who Gets Out

Trump's 100% Pharma Tariff: Who Pays, Who Gets Out